An inhibitor of FBXO3 (IC50 = 0.9 μg/mL for Il-1β release); decreases FBXO3-FBXL2 interaction in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2; lowers expression of TRAF1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated PBMCs; reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis when administered at a dose of 100 μg, i.p., per animal; reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema,